SCHEMBL16509249

SCHEMBL16509249

Cc1ccc2nc(-c3cccc(Br)c3)n(O)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.50
KDM4E B2RXH2 6/20 0.50
NPC1 O15118 5/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
RAB9A P51151 4/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
GAA P10253 2/20 0.50
LMNA P02545 3/20 0.49
TSHR P16473 1/20 0.49
HSD17B10 Q99714 1/20 0.49
KMT2A Q03164 8/20 0.47
MEN1 O00255 7/20 0.47
AVPR1A P37288 1/20 0.47
ATM Q13315 1/20 0.47
ALDH1A1 P00352 2/20 0.44
CYP2D6 P10635 1/20 0.44
HTT P42858 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16509299 0.90 KDM4E (0.56) MAPTKDM4ENPC1SMN1; SMN2RAB9A
SCHEMBL16509324 0.84 NPC1 (0.50) MAPTKDM4ENPC1SMN1; SMN2RAB9A
SCHEMBL14922007 0.83 KDM4E (0.69) MAPTKDM4ENPC1SMN1; SMN2RAB9A
SCHEMBL16509223 0.83 RAB9A (0.50) MAPTKDM4ENPC1SMN1; SMN2RAB9A
SCHEMBL16509264 0.81 KDM4E (0.48) MAPTKDM4ENPC1SMN1; SMN2RAB9A
SCHEMBL16509242 0.81 KDM4E (0.49) MAPTKDM4ENPC1SMN1; SMN2RAB9A
SCHEMBL16509297 0.80 NPC1 (0.47) MAPTKDM4ENPC1SMN1; SMN2RAB9A
SCHEMBL12325422 0.79 MAPT (0.55) MAPTKDM4ENPC1SMN1; SMN2RAB9A
SCHEMBL16509210 0.79 PRSS1 (0.48) MAPTKDM4ENPC1SMN1; SMN2RAB9A
SCHEMBL16509325 0.79 PARP1 (0.53) KDM4ENPC1SMN1; SMN2RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306611-A1 Transcription factor modulating compounds and methods of use thereof PARATEK PHARMACEUTICALS, INC. (US) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306611-A1 Transcription factor modulating compounds and methods of use thereof JUN, CREBBP, TFEB MAPT 4415/4885KDM4E 360/4885NPC1 3055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.